The landscape of biologics discovery is rapidly evolving, driven by breakthroughs in AI, an influx of high-quality datasets, and regulatory momentum supporting in silico approaches. As industry leaders look to streamline R and D and de-risk development, there is a critical need for cutting-edge tools in modeling, characterization, screening, and developability.